Hepatitis C - Valeant says Viramidine did not meet efficacy goal

Valeant says Viramidine did not meet efficacy goal
Reuters - NEW YORK, March 21 (Reuters) - Valeant Pharmaceuticals International (VRX.N: Quote , Profile , Research ) said on Tuesday a late-stage trial of its chronic hepatitis C treatment Viramidine did not meet the efficacy goal on an overall basis. It said

Highlights of rising and falling U.S. stocks
Investors Business Daily - Bally Total Fitness Holding ( BFT ) shares ended Tuesday's session with a 14.7% gain following a report that Virgin Group, run by billionaire Richard Branson, is mulling a takeover of the company. See full story. Shares of Corus Group Plc ( CGA

Cuban Combined Therapy Against Chronic Hepatitis C
Ahora.cu - A Cuban combination therapy for the treatment of chronic Hepatitis C is to be put on the market by the Heber Biotec S.A. company in Latin America, Asia, Africa, the Middle East and Europe, where this firm has registered the Heberon Alfa R (human

Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to